Abstract
Introduction: Acute heart failure (HF) remains one of the main factors contributing to increased mortality in patients with diabetes mellitus. Copeptin is the Cterminal portion of anti-diuretic hormone (ADH) and is secreted in equimolar amounts in acute HF patients. Methods: The Biomarkers in ACute Heart failure (BACH) trial was conducted to test multiple novel biomarkers in patients with heart failure presenting to the emergency department with dyspnea. This analysis aims to evaluate copeptin as a prognostic factor for 90-day mortality, specifically in diabetic patients. Results: Univariate analysis showed MR-proADM significant in predicting all-cause 90-day mortality in non-diabetics (OR 11.18 (1.86-66.9); p50.008) and copeptin in diabetics (OR 3.20 (1.26-8.12); p50.014). On multivariate analysis copeptin (p50.007) and age (p50.003) were significant predictors after adjusting for age, gender, history of chronic renal failure, congestive heart failure and coronary artery disease. Conclusion: Copeptin elevation predicts increased mortality in diabetic patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
